[{"from": "human", "value": "What can you tell me about this molecule? [C][O][C][=C][C][=C][Branch2][Ring1][#Branch1][C][=C][N][=C][Ring1][=Branch1][C][=C][Ring1][#Branch2][O][C][C][C][N][C][C][O][C][C][Ring1][=Branch1][O][C][=C][Branch2][Ring2][Branch1][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][Branch1][Branch1][C][C][Ring1][Ring1][C][=Branch1][C][=O][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable small molecule with potential antineoplastic activity. Foretinib binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling."}]